Rejected from Nature Genetics? The 7 Best Journals to Submit Next

• "The study is well-executed but the findings are expected.": Your GWAS confirmed associations that the field predicted. The statistical rigor is fine, but the results don't surprise anyone. Nature Genetics wants discoveries, not confirmations.

• "Single-gene characterization without broader genetic context.": You did beautiful functional work on one gene, but Nature Genetics wants to know how it fits into the genetic architecture of the trait or disease. Single-gene papers need to reveal something about gene regulation, genetic interactions, or functional genomics that extends beyond the specific gene.

• "Insufficient sample size for current standards.": The field has moved fast. A case-control study with 2,000 samples was competitive in 2015. In 2026, Nature Genetics expects tens of thousands at minimum for common-variant studies.

• "The findings are primarily relevant to specialists.": Your rare disease genetics paper is excellent, but the implications are limited to that disease community. Nature Genetics wants broader lessons about gene function, regulation, or genetic architecture.

Nature Genetics editors can transfer manuscripts to:

• Nature Communications (IF ~16) - Broad scope, ~14% acceptance rate- Communications Biology (IF ~5) - Solid biology- Nature Medicine (IF ~50) - If the disease/clinical implications are strongA Nature Genetics to Nature Communications transfer is common for papers that are solid genetics but didn't meet the "change how the field thinks" threshold. These transfers carry credibility with the receiving editor.

Before choosing your next journal, a Nature Genetics manuscript fit check can tell you whether the issue was scope or something more fundamental to address first.

• GWAS rejected for "insufficient novelty"?: AJHG is the strongest alternative for human GWAS. PNAS is strong for population-level studies. If the analytical method is novel, Genome Biology may value the computational contribution.

• Single-gene study rejected for "too narrow"?: Submit to the disease-specific journal (JCI for disease mechanisms, specialty journals for clinical genetics) or to AJHG if the genetic characterization is thorough.

• Genomics technology paper rejected?: Genome Biology for computational tools, Genome Research for sequencing-based methods, Nature Methods if the technology has broad life science applicability.

• Rejected after peer review?: Fix reviewer concerns. Nature Genetics reviewers overlap heavily with AJHG and Genome Research reviewers. Submitting the same manuscript risks the same criticisms.

• Don't inflate the novelty claim: If Nature Genetics said the findings were expected, don't add stronger language to your abstract and hope a different journal doesn't notice. Instead, submit to a journal where confirming important genetic associations is valued (AJHG, PNAS).

• Add functional follow-up if possible: If Nature Genetics wanted functional characterization of your GWAS hits and you can do it in 2-3 months, consider doing so. AJHG and other journals will also increasingly expect it.

• Reframe for the new audience: AJHG readers are human geneticists. Genome Research readers are genomics technologists. PLOS Genetics readers span all of genetics. Adjust your framing accordingly.

AJHG is the flagship journal of the American Society of Human Genetics and the most natural home for human genetics papers that Nature Genetics found too specialized. AJHG publishes GWAS, rare variant analyses, population genetics, genetic epidemiology, and functional genetics with a human focus. Where Nature Genetics requires your findings to reshape the entire field, AJHG values strong genetics that advances our understanding of human genetic variation and disease. A well-powered GWAS with careful analysis that didn't clear Nature Genetics' novelty bar can be an excellent AJHG paper.

Best for: Human disease genetics, GWAS with moderate sample sizes, population genetics, genetic epidemiology, rare variant studies.

Genome Research occupies a unique niche combining genomics technology development with biological discovery. The journal is particularly strong for papers that apply new computational or sequencing approaches to answer genetic questions. If Nature Genetics rejected your paper because the genomics methodology was the primary contribution rather than the genetic finding, Genome Research will value the technical innovation. The journal also publishes more model organism genetics than Nature Genetics typically considers.

Best for: Genomics technology applied to genetics, epigenomics, chromatin biology, model organism genetics, functional genomics methods.

Genome Biology is the leading journal for computational genomics, bioinformatics tools, and large-scale genomic analysis. If your paper involves a new analysis method, benchmarking study, or computational resource for the genetics community, Genome Biology values that contribution even if the biological discovery is moderate. The journal also publishes major community resources: reference datasets, atlas papers, and standardized pipelines. If your paper generates data or tools that others will build on, Genome Biology is where it will have the most impact.

Best for: Computational genomics, analysis methods, community resources, single-cell genomics tools, benchmarking studies.

PNAS publishes genetics research across all organisms and approaches. For genetics papers that don't fit the specific mandates of genetics-focused journals but represent solid science, PNAS provides a broad home. The journal values rigor and completeness without requiring the "change the field" novelty that Nature Genetics demands. PNAS has both direct submission and contributed (NAS member-sponsored) tracks. If you have a relationship with an NAS member in genetics, the contributed track can provide a faster route.

Best for: Genetics research across organisms, population genetics, evolutionary genetics, well-executed genetic studies that advance the field without necessarily being transformative.

For genetics papers that are clearly good science but didn't meet Nature Genetics' impact threshold, Nature Communications is the most practical high-impact alternative. The ~8% acceptance Nature Communications transfer is the most common redirect within the Nature Portfolio. Take it if offered.

Best for: Solid genetics papers that fell just below Nature Genetics' impact bar. Interdisciplinary genetics work.

PLOS Genetics is the top open-access genetics journal. It publishes across all of genetics, from model organisms to human populations, and values both discovery and methodology. The journal is particularly receptive to non-human genetics: plant genetics, Drosophila genetics, yeast functional genomics, and evolutionary genetics across species. If Nature Genetics rejected your paper for being "too focused on one organism" or "too specialized within genetics," PLOS Genetics is more tolerant of niche topics, especially for non-human work.

Best for: Model organism genetics, plant genetics, evolutionary genetics, functional genomics, and genetic studies in understudied organisms.

HMG is a solid mid-tier journal for human disease genetics. It publishes gene identification studies, functional characterization of disease variants, and genetic epidemiology. For papers that Nature Genetics found too disease-specific, HMG provides a focused audience of human disease geneticists.

Best for: Human disease variant characterization, functional studies of disease-associated loci, rare disease genetics.

• How to choose a journal for your paper
• Signs your paper is not ready to submit
• What pre-submission peer review includes

Before you resubmit, run your manuscript through a manuscript scope and readiness check to check fit, structure, and editorial risk before the next submission.

In our pre-submission review work with manuscripts targeting Nature Genetics, four patterns generate the most consistent desk rejections worth knowing before resubmission.

GWAS or association study without functional follow-up of the top findings. The field has moved substantially beyond association discovery. We see this failure as the most common pattern in Nature Genetics desk rejections we review: genome-wide association studies presenting discovery results with ranked loci but without functional characterization of at least the leading associations. In our review of Nature Genetics submissions, we find that editors consistently require fine-mapping, gene regulation data, functional screening, or independent cohort validation of the key hits before accepting a large-scale genetics paper.

Sample sizes that do not meet current field standards for the phenotype studied. In a field where analyses of biobanks with hundreds of thousands of participants are routine, small-to-moderate sample sizes face an inherently competitive disadvantage at Nature Genetics. We see papers in this category regularly: well-analyzed studies in 2,000-10,000 participants for common complex traits where the current power requirements are substantially higher. Exceptions exist for understudied populations and rare traits, but they require exceptional novelty or analytical innovation to compensate.

Confirmatory findings that align with field predictions. Nature Genetics wants discoveries that rewrite understanding, not papers that confirm what the field expected based on prior biological knowledge or preliminary signals. We see this pattern in Nature Genetics submissions we review present statistically robust associations or genetic findings where the biological direction was already anticipated from existing literature.

Single-gene functional characterization without connection to genetic architecture or broader disease biology. Functional work on a specific gene is publishable at Nature Genetics when it reveals something about how the genetic architecture of a trait works, how gene regulation functions in disease context, or how genetic variants affect molecular phenotypes. Single-gene papers without that broader genetic insight consistently face scope redirection.

SciRev community data for Nature Genetics confirms desk decisions typically within 1-2 weeks, consistent with the Nature Portfolio editorial cadence.